Statements (23)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:chemical_compound
|
gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
gptkbp:ATCCode |
L01EB04
|
gptkbp:CASNumber |
gptkb:162045-06-9
|
gptkbp:developedBy |
gptkb:AstraZeneca
|
gptkbp:hasMolecularFormula |
C28H33N7O2
|
gptkbp:hasSMILES |
CN(C)CCNC1=CC(=C(C=C1OC)NC2=NC=CC(=C2)C3=CN(C4=CC=CC=C34)C)C=O
|
gptkbp:hasUNII |
7A5I1C1W3F
|
https://www.w3.org/2000/01/rdf-schema#label |
162045-06-9
|
gptkbp:IUPACName |
gptkb:N-(2-{2-Dimethylamino)ethyl}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
|
gptkbp:mechanismOfAction |
gptkb:EGFR_tyrosine_kinase_inhibitor
|
gptkbp:molecularWeight |
499.6 g/mol
|
gptkbp:name |
gptkb:Osimertinib
|
gptkbp:PubChem_CID |
gptkb:DB09330
CHEMBL3185146 71496458 |
gptkbp:routeOfAdministration |
oral
|
gptkbp:synonym |
gptkb:Tagrisso
gptkb:AZD9291 |
gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
|
gptkbp:bfsParent |
gptkb:D08513
|
gptkbp:bfsLayer |
7
|